BridgeBio rises as late-stage trial of muscle-wasting drug meets all goals

Shares of drugmaker BridgeBio Pharma BBIO.O rise 10.5% to $60, highest in over four years

Co says its experimental drug BBP-418 met all the goals in a late-stage trial for a type of limb-girdle muscular dystrophy, a rare muscle-wasting disease

Drug boosted levels of key muscle protein and cut muscle damage marker CK by 82% from initial levels- BBIO

Co says treated patients showed better walking speed and lung function vs placebo at 12 months

BBIO plans to file for U.S. FDA approval in first half of 2026

Including session's move, stock up ~98% YTD